Determination of serum zinc-alpha-2-glycoprotein in patients with metabolic syndrome by a new ELISA.
OBJECTIVE
To develop an assay for the determination of ZAG in human serum, and to investigate its clinical relevance as a marker of metabolic syndrome.


METHODS
A new sandwich ELISA was introduced and clinically tested.


RESULTS
ZAG serum level did not differentiate healthy subjects (27.4+/-8.3 mg/L; N=132) from patients with metabolic syndrome (24.9+/-8.1; N=92). ZAG correlated with glucose, creatinine and uric acid.


CONCLUSIONS
The immunoassay offers a new research tool for glucose metabolism.
Stejskal
D
D
Department of Laboratory Medicine and Department of Medicine, Sternberk Hospital, Jivavská 20, Sternberk, Czech Republic. david.stejskal@nemstbk.cz
Karpísek
M
M
Reutová
H
H
Stejskal
P
P
Kotolová
H
H
Kollár
Peter
P
D000368:Aged; D001786:Blood Glucose / Q000378:metabolism; D003404:Creatinine / Q000097:blood; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005260:Female; D006801:Humans; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood*; D008875:Middle Aged; D029589:Seminal Plasma Proteins / Q000097:blood*; D014527:Uric Acid / Q000097:blood; D000090203:Zn-Alpha-2-Glycoprotein
D001786:Blood Glucose; D029589:Seminal Plasma Proteins; D000090203:Zn-Alpha-2-Glycoprotein; D014527:Uric Acid; D003404:Creatinine